Guanghua Wutong Fund

RootPath Genomics, Inc. is a biotechnology company founded in 2017 and headquartered in Cambridge, Massachusetts. The company specializes in developing a next-generation T-cell therapy platform that integrates precision medicine with cancer immunotherapy. By focusing on the analysis and manipulation of individual immune cells, RootPath aims to enhance immune responses and improve cell therapy efficacy. Its innovative technologies allow for precise monitoring and modulation of the immune system, which is intended to revolutionize the diagnosis and treatment of cancer.

Strongest Laser is a high-power fiber laser equipment developer.

Rona Therapeutics is an innovative RNA therapeutics platform focused on the discovery, development, and commercialization of modular and programmable RNA medicines. The company specializes in oligonucleotide therapies, RNA editing, and polymeric molecules, aiming to create transformative RNA therapies that can significantly impact disease treatment across various therapeutic areas. Rona Therapeutics is committed to developing proprietary technologies that enhance the specificity, stability, and longevity of therapeutic effects. To support its mission, the company is establishing state-of-the-art facilities to advance nucleic acid synthesis, delivery platforms, and RNA biology. Through its efforts, Rona Therapeutics seeks to improve patient health outcomes and foster an environment conducive to innovation and excellence in RNA medicine.

Hexaell Biotechnology Co., Ltd is an innovative start-up focused on developing advanced solutions for severe liver diseases through stem cell technology and bio-artificial organs. The company has licensed cutting-edge technologies, specifically iHep and HiHep, from the Chinese Academy of Sciences, which are foundational to its approach in creating medical devices aimed at replacing liver function and treating liver failure. Hexaell's research and development efforts have led to promising clinical applications, including successful pilot studies involving six liver failure patients at leading hepatopathy centers in China. By harnessing cell differentiation and production technology, Hexaell aims to provide patients with new and effective treatment options for liver-related health challenges.

C Ray Therapeutics develops healthcare advancements through nuclear medicine. It was founded in 2020.

Qinglan Jichuang is a domestic high-performance intelligent endoscope innovative enterprise.

Full-Life Technologies specializes in developing and commercializing radiopharmaceuticals for cancer therapy. It offers research and development, production, and distribution services within the radiotherapy sector, aiming to enhance patient outcomes through innovative nuclear medicine solutions.

Full-Life Technologies specializes in developing and commercializing radiopharmaceuticals for cancer therapy. It offers research and development, production, and distribution services within the radiotherapy sector, aiming to enhance patient outcomes through innovative nuclear medicine solutions.

Illumax is a company that specialises in the research and development of single-serve chemiluminescence, single-serve flow fluorescence, and laboratory automation technologies. It also offers the industry an open ecological platform for chemiluminescence and flow fluorescence.

Jinjiang Electronic Technology is a med-tech company focused on the research and development as well as the manufacture of advanced medical equipment designed to enhance patient care in the field of cardiac electrophysiology. The company offers a range of innovative products, including a 3D cardiac mapping system, electrophysiology recording system, cardiac RF ablation generator, and irrigation pump. These devices provide comprehensive solutions aimed at diagnosing and treating arrhythmias, ultimately improving the quality of life for patients with heart conditions.